Business Standard

Bal Pharma Share Price

Know More
NSEBSE

98.35-1.00 (-1.01%)

12:00 AM,16th Apr 2024

99.30-0.05 (-0.05%)

12:00 AM,16th Apr 2024

BSE : 524824

NSE : BALPHARMA

Sector : Health care

ISIN Code : INE083D01012

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Apr 16 2024 | 12:00 AM IST

Market Cap (₹ Cr)

155

Turnover (₹ Cr)

0.01

Volume (Shares)

12121

Face Value

10

52-WK High

132.45

52-WK High Date

02 Feb 2024

52-WK Low

69.60

52-WK Low Date

17 Apr 2023

All Time High

167.90

All Time High Date

13 Jan 2016

All Time Low

13.00

All Time Low Date

21 Jun 2013

Bal Pharma Ltd

Bal Pharma Ltd (BPL) a member of the Mcro Laboratories Group was incorporated as a private limited company in May '87. In Mar.'90 BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations -- paracetamol aluminium hydroxide povidone iodine alprazolam gliclazide griseofulvin lactobacillus rifampicin piroxicam amoxycillin etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 1997-98 the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN CAFIMOL & CORTIDERM.The company has added further product range Zanovid Aziwin Dry Syrup Meloxi Ocium - M Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range the company has introduced Cardiac Specialities Products. To market these products a new division named SERVETUS has started functioning during 2001. New products like AmilorideBenzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17 it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide Ebastine Amiloride HCL Benzydamine HCL Pregablin etc located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 2017-18 the Company acquired 100% stake and management control of Golden Drugs Private Ltd an Udaipur Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug'smanufacturing unit at Yadgir District Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form and as a combination with Metformin under the brand names SITABEND & SITABEND-M respectively in 2023.

Bal Pharma Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

155

EPS - TTM (₹) [S]

3.91

P/E Ratio (X) [S]

1.60

Face Value (₹) 10
Latest Dividend (%)10.00
Latest Dividend Date 18 Sep 2023
Dividend Yield (%) 1.00
Book Value Share (₹) [S]61.62
P/B Ratio (₹) [S]1.60
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

96.95

101.00

Week Low/High

96.95

106.00

Month Low/High

90.10

106.00

Year Low/High

69.60

132.00

All time Low/High

1.60

168.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-2.58%-3.29%-2.33-2.19%
1 Month3.96%3.85%0.410.57%
3 Month-13.99%-13.77%-0.250.52%
6 Month5.56%6.09%10.2412.24%
1 Year38.07%37.36%20.7124.23%
3 Year57.61%57.23%49.3851.51%

Company Info

Company Information

Managing Director : Shailesh Siroya

Independent Director : C V Srinivas

Executive Director : Himesh Virupakshaya

Independent Director : H S Venkatesh

Independent Director : Nicola Neeladri

Independent Director : Jatish Sheth

Whole-time Director : Kotian Chittananda Damodar

Company Sec. & Compli. Officer : Abdul Basith

Registered Office: 21 & 22 Bommasandra Indl Area, Hosur Road,Bangalore,Karnataka-560092 Ph:

Email:investor@balpharma.com

URL:http://www.balpharma.com